Longer exposure to HbA1c levels above target (i.e. HbA1c ≥64 mmol/mol (8%)) is associated with an increased risk of both micro-and macrovascular complications. Models that use a single point measurement of HbA1c as a predictor of outcomes are not necessarily a good representation of the risk to which an individual is exposed. Models that take into account multiple HbA1c measures show more pronounced associations with micro- and macrovascular outcomes. This was concluded in a study recently published in Diabetes Therapy. In this study the relation between different measures of glycemic exposure and micro-and macrovascular complications was assessed in type 2 diabetes patients in the PHARMO Database Network. Finding suggest that glycemic memory plays a role in the development of diabetic complications and that treatment inertia increases the risk of these outcomes in a broad population of diabetes patients who are not on target.
To read more, please click here.